Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
53 hedge funds and large institutions have $84M invested in Carisma Therapeutics in 2023 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 9 closing their positions.
387% more capital invested
Capital invested by funds: $17.3M → $84M (+$66.8M)
237% more call options, than puts
Call options by funds: $5.49M | Put options by funds: $1.63M
178% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 9
150% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 6
43% more funds holding
Funds holding: 37 → 53 (+16)
9.96% more ownership
Funds ownership: 13.84% → 23.8% (+10%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$8.99M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.14M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.41M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.29M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$1.28M |
| 2 |
DCM
Deuterium Capital Management
Clearwater,
Florida
|
-$159K |
| 3 |
WIM
Wittenberg Investment Management
Carlisle,
Massachusetts
|
-$145K |
| 4 |
Millennium Management
New York
|
-$111K |
| 5 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
-$61.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
National Bank of Canada
Montreal,
Quebec, Canada
| $438 | – | – | – |
|
52
Osaic Holdings
Scottsdale,
Arizona
| $219 | -$5.44K | -1,000 | -98% |
|
|
BCM
53
BML Capital Management
Zionsville,
Indiana
| – | -$1.28M | -411,398 | Closed |
|
|
DCM
54
Deuterium Capital Management
Clearwater,
Florida
| – | -$159K | -51,256 | Closed |
|
|
WIM
55
Wittenberg Investment Management
Carlisle,
Massachusetts
| – | -$145K | -46,703 | Closed |
|
|
56
Millennium Management
New York
| – | -$111K | -35,673 | Closed |
|
|
SWP
57
Stratos Wealth Partners
Beachwood,
Ohio
| – | -$61.7K | -19,899 | Closed |
|
|
JF
58
Jump Financial
Chicago,
Illinois
| – | -$54.4K | -17,542 | Closed |
|
|
VF
59
Virtu Financial
New York
| – | -$48K | -15,335 | Closed |
|
|
TIM
60
Tortoise Investment Management
White Plains,
New York
| – | -$620 | -200 | Closed |
|
CARM Hedge Fund Activity: Q2 2023 in Review
53 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q2 2023, worth a combined $84M — up 387% from $17.3M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new CARM positions and 9 closed out — a net gain of 16 holders — while 15 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $8.99M. The largest seller was BML Capital Management, exiting entirely with an estimated $1.28M sold.
- 53 institutional investors held Carisma Therapeutics (CARM) as of Q2 2023, up from 37 in Q1 2023.
- Funds reported $84M of Carisma Therapeutics stock for Q2 2023, up 387% quarter-over-quarter.
- 25 funds opened new Carisma Therapeutics positions in Q2 2023 and 9 closed out, a net change of +16 holders.
- The largest Carisma Therapeutics buyer in Q2 2023 was BlackRock, an estimated $8.99M added.
- The largest Carisma Therapeutics seller in Q2 2023 was BML Capital Management, an estimated $1.28M sold.
Based on aggregated 13F filings for Q2 2023.